BGNE short above 260$, target price 161$, about Mar 9, 2021.
Similar pattern of Aug 8, 2018.
Wait BGNE price reached 161$, start building long position.
It's not a good idea holding BGNE under 270$~260$
Long stop-Loss price : 259$
Short stop-loss price : 284$
Making a nice inverse h&s and this has potential of going lot higher. Need to identify which strike. I am not even sure if I will pull the trigger but hopefully someone can find this helpful. Checked the options and look expensive. r/r is not attractive imho.
BGNE had a huge gain today of 10.5% after the market turned down towards the end of the day on weak volume. On the other hand, BGNE rocketed on 47% above average volume (20).
Going along with this - During the recent weeks of the market correction, BGNE just barely went under the 21 day EMA and is still continually producing good earnings quarter after quarter....
We really want to enter this trade, but like always we make our plan first waite for the stock to hit a certain point and buy a massive amount of options for an easy 100%. St. Is bullish and Gan is confirming :D
Saucer on from Oct 10 to Mid January. Heavy volume on January 18 due to an offering.
1.18.18 - BGNE teamed up with CELG, receiving rights to market CELG's drugs in China for the next 10 years. BGNE acquired $750m from the offering which looks positive for new R&D of their drugs.
Further analysis: Failed breakout at the 120 range on weak volume. Choppy...
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
NASDAQ
